Dr. Sam Jackson leads clinical drug development efforts at Alkahest, a biotechnology company whose mission is to enrich the health and vitality of humankind through transformative therapies that counterbalance the aging process. Dr. Jackson has extensive experience in drug development, most recently at Dynavax, where he led the Drug Safety Group and designed and conducted vaccine and asthma clinical trials. Dr. Jackson also led drug development teams at Genentech in diverse therapeutic areas including immunology, hepatology and ophthalmology. He started his career in industry at Amgen, where he was responsible for the safety for a broad array of molecules in various stages of development.

Dr. Jackson has an undergraduate degree from Stanford and is a graduate of the MD/MBA program at the University of Pennsylvania/Wharton. He completed his residency in emergency medicine at UC Davis in Sacramento, California, and his fellowship in medical toxicology at Banner Good Samaritan Hospital in Phoenix, Arizona.